Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
Abstract: In 2022, the European LeukemiaNet (ELN) risk stratification for patients with acute myeloid leukemia (AML) has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) by evaluating 1570 patients with newly diagnosed AML (median age, 56 years) treated...
Saved in:
Similar Items
-
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
by: Adriano Venditti, et al.
Published: (2025-05-01) -
Prognostic analysis according to European LeukemiaNet 2022 risk stratification for elderly patients with acute myeloid leukemia treated with decitabine
by: Mihee Kim, et al.
Published: (2024-12-01) -
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
by: Christina Rautenberg, et al.
Published: (2025-04-01) -
Synthetic bone marrow images augment real samples in developing acute myeloid leukemia microscopy classification models
by: Jan-Niklas Eckardt, et al.
Published: (2025-03-01) -
Protective effects for HLA-B*40:01 and C*03:04 in NPM1-mutated AML: result of a large HLA association study
by: Elke Rücker-Braun, et al.
Published: (2025-06-01)